Balanced news tone
News Sentiment
4502 sentiment intelligence
Takeda Pharmaceutical Company Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
35 relevant articles
News tone and price action are not far from neutral.
85/100 classification confidence.
directly relevant articles
high-authority source matches
+3.2% over one week, -3.7% over four weeks, trend inactive, and near fair-value range.
Takeda Stock - analyst focus on pipeline and earnings outlook
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
85/100 classification
One-week reaction
3.2%
Price confirming higher
Trend fit
Trend inactive
-3.7% over four weeks
Fair value
21.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
22
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
AD HOC NEWS
Direct company coverage
Takeda Stock - analyst focus on pipeline and earnings outlook
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 19:04
- Source
- AD HOC NEWS
Market source
Direct company coverage
Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 18:13
- Source
- Market source
GuruFocus
Direct company coverage
Takeda Pharmaceutical Co Ltd (TSE:4502) Stock Price, Trades & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 05:49
- Source
- GuruFocus
simplywall.st
Direct company coverage
Is Zasocitinib’s Phase 3 Beat And New Shelf Filing Altering The Investment Case For Takeda Pharmaceutical (TSE:4502)?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Jun 2026 17:22
- Source
- simplywall.st
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): oncology focus meets pricing headwinds
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 20:42
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): New drug approvals and pipeline milestones in focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 20:33
- Source
- AD HOC NEWS
simplywall.st
Direct company coverage
A Look At Takeda Pharmaceutical (TSE:4502) Valuation As New CEO And Transformation Plan Take Shape
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jun 2026 07:00
- Source
- simplywall.st
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical (ADR) stock (US8740602052): shares fall in New York after shelf registration u
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 01 Jun 2026 23:02
- Source
- AD HOC NEWS
Stock Titan
Direct company coverage
Takeda (NYSE: TAK) files JPY 240B Japan shelf to support LTIP shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
Takeda Pharmaceutical (TSE:4502) Valuation Check As Short Term Weakness Meets Longer Term Returns
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Takeda Workforce Cuts Reshape Costs While Valuation Signals Possible Upside
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 May 2026 07:00
- Source
- simplywall.st
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): Japan sales and U.S. exposure stay in focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): oncology and rare disease focus after latest earnings up
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): earnings in focus as investors weigh legal risks
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 19 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical Co Ltd stock (JP3730800003): earnings beat but softer EPS outlook
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 16 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): recent earnings and Rybelsus biosimilar plans in focus
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 May 2026 07:00
- Source
- AD HOC NEWS
marketscreener.com
Direct company coverage
Pharmaceutical company Takeda announces sweeping cutbacks; impact on Belgian division unclear
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- marketscreener.com
simplywall.st
Direct company coverage
Takeda Pharmaceutical Company Limited Just Recorded A 8.6% EPS Beat: Here's What Analysts Are Forecasting Next
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- AD HOC NEWS
Morningstar
Direct company coverage
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Morningstar
simplywall.st
Direct company coverage
Takeda Pharmaceutical (TSE:4502) Net Margin Improvement Tests Bearish Profitability Narratives
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- simplywall.st
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical stock (JP3730800003): Q4 2026 earnings report released
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- AD HOC NEWS
Market source
Direct company coverage
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
AD HOC NEWS
Direct company coverage
Takeda Pharmaceutical Co Ltd stock (JP3730800003): Japan’s largest pharma firm with strong US expo
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- AD HOC NEWS
Market source
Direct company coverage
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Is Takeda Pharmaceutical (TSE:4502) Pricing Look Compelling After Strong Multi‑Year Share Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Mixed Pipeline News On DNL593 And Zasocitinib
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Apr 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Takeda Pharmaceutical Company Limited (TSE:4502) Goes Ex-Dividend Soon
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Takeda (NYSE: TAK) Japan Pharma chief details shares, RSUs and tax awards
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After Strong Multi‑Period Shareholder Returns
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Mar 2026 07:00
- Source
- Market source